Beth Reboussin to Estrogen Replacement Therapy
This is a "connection" page, showing publications Beth Reboussin has written about Estrogen Replacement Therapy.
Connection Strength
0.201
-
Hu P, Greendale GA, Palla SL, Reboussin BA, Herrington DM, Barrett-Connor E, Reuben DB. The effects of hormone therapy on the markers of inflammation and endothelial function and plasma matrix metalloproteinase-9 level in postmenopausal women: the postmenopausal estrogen progestin intervention (PEPI) trial. Atherosclerosis. 2006 Apr; 185(2):347-52.
Score: 0.061
-
Ursin G, Palla SL, Reboussin BA, Slone S, Wasilauskas C, Pike MC, Greendale GA. Post-treatment change in serum estrone predicts mammographic percent density changes in women who received combination estrogen and progestin in the Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. J Clin Oncol. 2004 Jul 15; 22(14):2842-8.
Score: 0.057
-
Greendale GA, Reboussin BA, Slone S, Wasilauskas C, Pike MC, Ursin G. Postmenopausal hormone therapy and change in mammographic density. J Natl Cancer Inst. 2003 Jan 01; 95(1):30-7.
Score: 0.051
-
Reuben DB, Palla SL, Hu P, Reboussin BA, Crandall C, Herrington DM, Barrett-Connor E, Greendale GA. Progestins affect mechanism of estrogen-induced C-reactive protein stimulation. Am J Med. 2006 Feb; 119(2):167.e1-8.
Score: 0.016
-
Crandall C, Palla S, Reboussin B, Hu P, Barrett-Connor E, Reuben D, Greendale G. Cross-sectional association between markers of inflammation and serum sex steroid levels in the postmenopausal estrogen/progestin interventions trial. J Womens Health (Larchmt). 2006 Jan-Feb; 15(1):14-23.
Score: 0.016